31 May, 2016 by The TZ Newswire Staff Comments Off on Allstate Stock To Trade Ex-Dividend (ALL)
Allstate Stock To Trade Ex-Dividend (ALL)
Allstate will send its dividend payment on July 1 to shareholders of record as of June 3.
31 May, 2016 by The TZ Newswire Staff Comments Off on Capitol Report: SEC forms task force to stamp out misleading financial statements
Capitol Report: SEC forms task force to stamp out misleading financial statements
The Securities and Exchange Commission is taking another step to crack down on corporate use of numbers that the agency fears deceives investors.
read more
31 May, 2016 by The TZ Newswire Staff Comments Off on The stock market is getting more comfortable with a Trump presidency
The stock market is getting more comfortable with a Trump presidency
Wall Street seems to be growing more comfortable with the possibility of Donald Trump winning the presidential election.
31 May, 2016 by The TZ Newswire Staff Comments Off on Powervault Extends Third Crowdcube Campaign: Has Raised Over £1.2M From Nearly 700 Investors
Powervault Extends Third Crowdcube Campaign: Has Raised Over £1.2M From Nearly 700 Investors
Last week, UK-based Powervault announced that it has decided to extend its third Crowdcube campaign for two more weeks. This news comes after the energy company successfully secured £1 million. The company announced in a recent update: “We have decided to extend our campaign until 10th June…. Read More
31 May, 2016 by The TZ Newswire Staff Comments Off on The Wall Street Journal: Carl Icahn takes ‘large’ stake in Allergan
The Wall Street Journal: Carl Icahn takes ‘large’ stake in Allergan
Billionaire investor Carl Icahn said he has taken a “large” stake in Allergan PLC, and threw his support behing the drug maker’s chief executive, Brent Saunders.
read more
31 May, 2016 by The TZ Newswire Staff Comments Off on Williams Companies Inc. Finally Faces Reality
Williams Companies Inc. Finally Faces Reality
31 May, 2016 by The TZ Newswire Staff Comments Off on Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.
Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.
Biotech stocks haven’t performed very well over the past 12 months. A couple of them have seen downright dismal results. Shareholders of Celldex Therapeutics, Inc. (NASDAQ: CLDX) have watched the stock tank over 80% in the last year. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) doesn’t look much better, with a drop of nearly 70% during the same period.